{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=eptacog+alfa+%28activated%29&page=2",
    "query": {
      "intervention": "eptacog alfa (activated)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 40,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=eptacog+alfa+%28activated%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=eptacog+alfa+%28activated%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T10:01:02.004Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00127283",
      "title": "Recombinant Factor VIIa in Acute Intracerebral Haemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Intracerebral Haemorrhage"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 829,
      "start_date": "2005-05",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 77,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00127283"
    },
    {
      "nct_id": "NCT06883240",
      "title": "An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Von Willebrand Disease, Type 3"
      ],
      "interventions": [
        {
          "name": "Von Willebrand Factor Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Von Willebrand Factor Concentrates and Factor VIII Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Factor VIII Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Activated Factor VII",
          "type": "DRUG"
        },
        {
          "name": "Activated Prothrombin Complex Concentrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2025-04-29",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06883240"
    },
    {
      "nct_id": "NCT01105546",
      "title": "rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A With Inhibitors"
      ],
      "interventions": [
        {
          "name": "recombinant activated factor VII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "8 Years",
        "sex": "MALE",
        "summary": "Up to 8 Years · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2010-12",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2013-04-08",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Kansas City, Missouri",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01105546"
    },
    {
      "nct_id": "NCT01352143",
      "title": "Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiopulmonary Bypass"
      ],
      "interventions": [
        {
          "name": "Recombinant activated factor VII",
          "type": "DRUG"
        },
        {
          "name": "Prothrombin Complex Concentrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Days",
        "sex": "ALL",
        "summary": "Up to 30 Days"
      },
      "enrollment_count": 24,
      "start_date": "2011-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2013-11-20",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01352143"
    },
    {
      "nct_id": "NCT05695391",
      "title": "Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Coagulation Factor VIIa (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Laboratoire français de Fractionnement et de Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2024-06-07",
      "completion_date": "2025-07-07",
      "has_results": true,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • New Orleans, Louisiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05695391"
    },
    {
      "nct_id": "NCT05281718",
      "title": "Factor IX as Adjunctive Therapy to Emicizumab (EMIX)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Factor IX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tulane University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "12 Years to 120 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2022-08-01",
      "completion_date": "2024-07-14",
      "has_results": false,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 2,
      "location_summary": "Metairie, Louisiana • New Orleans, Louisiana",
      "locations": [
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05281718"
    },
    {
      "nct_id": "NCT04647227",
      "title": "SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A With Inhibitor",
        "Hemophilia B With Inhibitor"
      ],
      "interventions": [
        {
          "name": "coagulation factor VIIa [recombinant]-jncw",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Thrombosis and Hemostasis Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 55,
      "start_date": "2021-06-28",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04647227"
    },
    {
      "nct_id": "NCT01625390",
      "title": "A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A, Hemophilia B"
      ],
      "interventions": [
        {
          "name": "BAY86-6150",
          "type": "DRUG"
        },
        {
          "name": "eptacog alfa [activated]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "62 Years",
        "sex": "MALE",
        "summary": "12 Years to 62 Years · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2012-06",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2015-07-01",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01625390"
    },
    {
      "nct_id": "NCT01561950",
      "title": "Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Haemostasis",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 91,
      "start_date": "2008-05",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2016-11-23",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 1,
      "location_summary": "Neptune City, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561950"
    },
    {
      "nct_id": "NCT00323570",
      "title": "Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Trauma"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2006-05",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2012-06-27",
      "last_synced_at": "2026-10-06T10:01:02.004Z",
      "location_count": 42,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 37 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323570"
    }
  ]
}